Canine Mammary Tumors (CMTs) are prevalent in female dogs, particularly in those that are unspayed, while being rare in males (<1%). These tumors are predominantly malignant with diverse histological classifications and a high mortality rate. Solid carcinomas within CMTs represent a crucial focus of research due to their prevalence and varied prognostic implications. Understanding their biological behavior through detailed histological and immunohistochemical analyses is pivotal for developing tailored treatment strategies. The identification of specific subtypes of solid carcinomas allows for improved prognostication and therapeutic interventions, thereby potentially enhancing both the quality of life and survival rates of affected dogs. This study presents a case of an 8-year-old Pinscher diagnosed with solid arrangement carcinoma, characterized by positive CK14 staining indicative of poorly differentiated basaloid carcinoma. The dog underwent chemotherapy with doxorubicin and carboplatin. This case underscores the significance of precise immunohistochemical and histological classification of CMTs in facilitating accurate prognosis and treatment planning, even for small nodules. Notably, the dog's survival of 420 days surpassed the typical median survival for solid carcinomas, highlighting the potential for enhanced outcomes with appropriate clinical management. Overall, this case emphasizes the critical need for comprehensive clinical, histopathological, and molecular evaluations in the intricate management of canine CMTs, aiming to optimize treatment strategies and improve clinical outcomes.
For a considerable period, microRNAs (miRNAs) were commonly regarded as mere intermediate products devoid of any function. In the past decade, the increasing number of publications on the involvement of miRNAs in oncogenesis and the progression of neoplasms has made them attractive targets, since the malfunction of miRNAs in cells can lead to the dysregulation of tumor suppressor genes and/or oncogenes. The study in question employs an integrative literature review methodology to investigate the role of microribonucleic acids (miRNAs) in the context of human breast neoplasms (HBNs) and canine mammary neoplasms (CMNs). The impetus for this research stems from the evolving understanding of miRNAs, which were previously regarded as intermediate products devoid of function. However, they are now recognized as significant players in oncogenesis. There are numerous similarities between epidemiological factors and histopathological aspects of human breast neoplasms (HBNs) and canine mammary neoplasms (CMNs). Computational analyses have also demonstrated miRNA similarity between HBNs and CMNs. These findings suggest that the dog may serve as a suitable model for studying HBNs. miRNA assessment can assist in the diagnosis of mammary neoplasms, as profiles reveal differential expression linked to early detection, prognosis, and treatment.
CMTs are biologically heterogeneous neoplasms for which reliable prognostic biomarkers remain limited. This study investigated the clinical significance of serum cancer antigen 15-3 (CA 15-3) and the immunohistochemical expression of Ki-67 and cyclooxygenase-2 (COX-2) in CMTs. Fifty-four female dogs with histologically confirmed CMTs and twelve healthy controls were prospectively evaluated. Serum CA 15-3 concentrations were measured before surgery and at 21 and 90 days post-mastectomy, while Ki-67 and COX-2 expression were assessed in tumor tissues. CA 15-3 was undetectable in controls and significantly higher in malignant than benign neoplasms (p < 0.05), with moderate correlations with clinical stage (s = 0.59), histological grade (s = 0.64), and the number of nodules (s = 0.42). Levels remained elevated in advanced stages despite surgery. ROC analysis identified a CA 15-3 cutoff of 3.01 IU/mL (AUC = 0.92) for discriminating malignant from benign tumors. Ki-67 correlated with histological grade (ρ = 0.41) but showed limited prognostic accuracy (AUC = 0.63). COX-2 expression lacked significant associations and showed poor discriminatory power (AUC = 0.44). Survival analyses did not identify significant differences among groups. Principal component analysis demonstrated clustering of aggressive CMTs according to biomarker profile. These findings suggest that serum CA 15-3 may represent a useful adjunct prognostic biomarker in canine mammary oncology, while the combination of serum and tissue biomarkers may improve prognostic stratification and may guide therapeutic decision-making in veterinary oncology. These findings support the growing role of biomarker panels in the clinical management of CMTs.